AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
voxilaprevir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| Hepatitis Virus C (HVC) protease inhibitors | 5242 | 1535212-07-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Voxilaprevir is a noncovalent, reversible inhibitor of the NS3/4A protease, which is necessary for the proteolytic cleavage of the HCV encoded polyprotein (into mature forms of the NS3, NS4A, NS4B, NS5A, and NS5B proteins) and is essential for viral replication. In a biochemical inhibition assay, voxilaprevir inhibited the proteolytic activity of recombinant NS3/4A enzymes from clinical isolates of HCV genotypes 1b and 3a with Ki values of 38 and 66 pM, respectively.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | PDK1,PDK2,PDK4 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 18, 2017 | FDA | GILEAD SCIENCES INC | |
| July 26, 2017 | EMA | GILEAD SCIENCES IRELAND UC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AP56 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections |
| FDA MoA | N0000182638 | HCV NS3/4A Protease Inhibitors |
| FDA EPC | N0000182639 | Hepatitis C Virus NS3/4A Protease Inhibitor |
| FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
| FDA MoA | N0000190107 | Organic Anion Transporting Polypeptide 1B1 Inhibitors |
| FDA MoA | N0000190108 | Organic Anion Transporting Polypeptide 1B3 Inhibitors |
| FDA MoA | N0000190113 | Breast Cancer Resistance Protein Inhibitors |
| CHEBI has role | CHEBI:22587 | antiviral agent |
Related Drugs by ATC class:
J05AP Antivirals for treatment of HCV infections 18 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chronic hepatitis C | indication | 128302006 | |
| Product containing ethinylestradiol | contraindication | 15432003 | |
| Pglycoprotein (Pgp) and/or strong cytochrome P450 (CYP) inducers | contraindication | 422728003 | |
| Dabigatran etexilate | contraindication | 700029008 | |
| Rosuvastatin | contraindication | 700067006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.64 | acidic |
| pKa2 | 1.22 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8334270 | March 21, 2028 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8334270 | March 21, 2028 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8580765 | March 21, 2028 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8580765 | March 21, 2028 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8735372 | March 21, 2028 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8735372 | March 21, 2028 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8957046 | March 21, 2028 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8957046 | March 21, 2028 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 9085573 | March 21, 2028 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 9085573 | March 21, 2028 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 7964580 | March 26, 2029 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 7964580 | March 26, 2029 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8633309 | March 26, 2029 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8633309 | March 26, 2029 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8889159 | March 26, 2029 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8889159 | March 26, 2029 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 9284342 | Sept. 13, 2030 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 9284342 | Sept. 13, 2030 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8618076 | Dec. 11, 2030 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8618076 | Dec. 11, 2030 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8575135 | Nov. 16, 2032 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8575135 | Nov. 16, 2032 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8921341 | Nov. 16, 2032 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8921341 | Nov. 16, 2032 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8940718 | Nov. 16, 2032 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 8940718 | Nov. 16, 2032 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 11116783 | Jan. 30, 2034 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 11116783 | Jan. 30, 2034 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 11338007 | June 1, 2037 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| 400MG;100MG;100MG | VOSEVI | GILEAD SCIENCES INC | N209195 | July 18, 2017 | RX | TABLET | ORAL | 11338007 | June 1, 2037 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Genome polyprotein | Polyprotein | INHIBITOR | Ki | 10.42 | DRUG LABEL | DRUG LABEL | |||
| Genome polyprotein | Polyprotein | INHIBITOR | Ki | 10.18 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| 0570F37359 | UNII |
| 4036863 | VANDF |
| C4507236 | UMLSCUI |
| CHEBI:755830 | CHEBI |
| L9P | PDB_CHEM_ID |
| CHEMBL3707372 | ChEMBL_ID |
| 89921642 | PUBCHEM_CID |
| DB12026 | DRUGBANK_ID |
| D10899 | KEGG_DRUG |
| 10143 | INN_ID |
| C000619503 | MESH_SUPPLEMENTAL_RECORD_UI |
| 736536005 | SNOMEDCT_US |
| 816106001 | SNOMEDCT_US |
| 32914 | MMSL |
| d08618 | MMSL |
| 017285 | NDDF |
| 1939323 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Vosevi | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61958-2401 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 34 sections |